Clinical Trial Update: Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating trastuzumab for HER2-positive Paget's disease of the vulva has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paget Disease of the Vulva

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Yale University | Conditions: Paget's Disease of the Vulva | Phase 2 | Status: WITHDRAWN